James Carmichael
Impact in
- Oncology top 0.05%
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment
Papers in
- Oncology 40
- Cancer Treatment and Pharmacology 12
- PARP inhibition in cancer therapy 11
- Lung Cancer Research Studies 4
- Drug Transport and Resistance Mechanisms 4
-
- Cancer therapeutics and mechanisms 4
- DNA Repair Mechanisms 3
- Co-authors
- William DeGraff (6 shared papers)John D. Minna (3 shared papers)Adi F. Gazdar (2 shared papers)James B. Mitchell (1 shared paper)Andrew Tutt (4 shared papers)Michael Friedländer (4 shared papers)Stan B. Kaye (4 shared papers)Ursula A. Matulonis (3 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)International Journal of Radiation Oncology*Biology*Physics (8 papers)Cancer Chemotherapy and Pharmacology (6 papers)Investigational New Drugs (2 papers)Anti-Cancer Drugs (2 papers)
- Partner nations
- United KingdomUnited StatesSwitzerland
In The Last Decade
James Carmichael
70 papers receiving 16.3k citations
James Carmichael's Hit Papers
Peers
Comparison fields: 5 of 154
- Oncology 9.3k
- Reproductive Medicine 1.8k
- Cancer Research 2.1k
- Molecular Biology 7.3k
- Genetics 2.4k
Countries citing papers authored by James Carmichael
This map shows the geographic impact of James Carmichael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Carmichael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Carmichael more than expected).
Fields of papers citing papers by James Carmichael
This network shows the impact of papers produced by James Carmichael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Carmichael. The network helps show where James Carmichael may publish in the future.
Co-authors
The 25 scholars most cited alongside James Carmichael, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 74 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Hit paper breakdown → | 1987 | 3546 |
| 2 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 2716 |
| 3 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1748 |
| 4 | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Hit paper breakdown → | 2012 | 1363 |
| 5 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1296 |
| 6 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Hit paper breakdown → | 2011 | 855 |
| 7 | Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Hit paper breakdown → | 2010 | 753 |
| 8 | Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer Hit paper breakdown → | 1999 | 702 |
| 9 | Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Hit paper breakdown → | 1987 | 630 |
| 10 | 2011 | 380 | |
| 11 | 2008 | 269 | |
| 12 | 2002 | 208 | |
| 13 | Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. | 2002 | 180 |
| 14 | 2008 | 165 | |
| 15 | 2013 | 156 | |
| 16 | 2011 | 126 | |
| 17 | 1989 | 116 | |
| 18 | 2004 | 114 | |
| 19 | 1992 | 94 | |
| 20 | 2010 | 74 |
About James Carmichael
James Carmichael is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Surgery and Genetics, having authored 74 papers that have together received 16.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), PARP inhibition in cancer therapy (11 papers), Nausea and vomiting management (7 papers), Lung Cancer Research Studies (4 papers), Chemotherapy-induced organ toxicity mitigation (4 papers), Drug Transport and Resistance Mechanisms (4 papers), Cancer therapeutics and mechanisms (4 papers) and DNA Repair Mechanisms (3 papers). The work is most often cited by research in Oncology (9.3k citations), Reproductive Medicine (1.8k citations), Cancer Research (2.1k citations), Molecular Biology (7.3k citations) and Genetics (2.4k citations). James Carmichael has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include William DeGraff, John D. Minna, Adi F. Gazdar, James B. Mitchell, Andrew Tutt, Michael Friedländer, Stan B. Kaye, Ursula A. Matulonis, Jan H.M. Schellens and Timothy A. Yap. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer Chemotherapy and Pharmacology, Investigational New Drugs and Anti-Cancer Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.